Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs The Coca-Cola Co K (KO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs The Coca-Cola Co K — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while The Coca-Cola Co K trades at $83.74 (market cap $359.21B). The key difference: The Coca-Cola Co K is far larger — about 9× Alnylam Pharmaceuticals, Inc.'s market cap, and The Coca-Cola Co K pays a 2.54% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | KO | |
|---|---|---|
Market Cap | $39.89B | $359.21B |
Sector | Health | Consumer Staples |
52-Week High | $491.22 | $84.14 |
52-Week Low | $278.09 | $65.67 |
Enterprise Value | $38.15B | $389.28B |
Volume | — | 14,630,257 |
Dividend Yield | — | 2.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Coca-Cola (KO) trades at $83.49, up 1.04% today, with a bullish technical signal from moving averages and strong analyst support. The company reported consistent earnings beats in recent quarters and maintains robust profitability with a 27.8% net income margin. Recent news highlights institutional buying and stable demand trends, though regional divergences exist.
The outlook is positive with a consensus price target of $89, offering ~6.6% upside. Key risks include high valuation multiples and macroeconomic sensitivity. The stock remains a core holding for dividend growth, supported by 64 consecutive years of dividend increases and solid cash flow generation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About The Coca-Cola Co K
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →
